Home › Research › Treatments
Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force
Boustani M, Peterson B, Hanson L, Harris R, Lohr KN, U.S. Preventive Services Task Force.. Annals of internal medicine, 2003-06-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Background Dementia is a large and growing problem but is often not diagnosed in its earlier stages. Screening and earlier treatment could reduce the burden of suffering of this syndrome. Purpose To review the evidence of benefits and harms of screening for and earlier treatment of dementia. Data sources MEDLINE, PsycINFO, EMBASE, the Cochrane Library, experts, and bibliographies of reviews. Study selection The authors developed eight key questions representing a logical chain between screening and improved health outcomes, along with eligibility criteria for admissible evidence for each question. Admissible evidence was obtained by searching the data sources. Data extraction Two reviewers abstracted relevant information using standardized abstraction forms and graded article quality according to U.S. Preventive Services Task Force criteria. Data synthesis No randomized, controlled trial of screening for dementia has been completed. Brief screening tools can detect some persons with early dementia (positive predictive value Conclusions Screening tests can detect undiagnosed dementia. In persons with mild to moderate clinically detected Alzheimer disease, cholinesterase inhibitors are somewhat effective in slowing cognitive decline. The effect of cholinesterase inhibitors or other treatments on persons with dementia detected by screening is uncertain.
What this study adds
Evidence grade: High
This is a narrative review. Screening tests can find some people with undiagnosed dementia, but no randomized trial of screening for dementia has been completed. In people whose mild to moderate Alzheimer disease is already clinically detected, cholinesterase inhibitors are somewhat effective at slowing cognitive decline, but whether these or other treatments help people found through screening is uncertain.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Boustani, M., Peterson, B., Hanson, L., Harris, R., Lohr, K. N., & U.S. Preventive Services Task Force. (2003). Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force. Annals of internal medicine. https://doi.org/10.7326/0003-4819-138-11-200306030-00015
Vancouver
Boustani M, Peterson B, Hanson L, Harris R, Lohr KN, U.S. Preventive Services Task Force. Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force. Annals of internal medicine. 2003. doi:10.7326/0003-4819-138-11-200306030-00015. PMID: 12779304.
BibTeX
@article{boustani2003-12779304,
author = {Boustani, M. and Peterson, B. and Hanson, L. and Harris, R. and Lohr, K. N. and {U.S. Preventive Services Task Force}},
title = {{Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force}},
journal = {Annals of internal medicine},
year = {2003},
doi = {10.7326/0003-4819-138-11-200306030-00015},
pmid = {12779304},
url = {https://doi.org/10.7326/0003-4819-138-11-200306030-00015}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Data extraction Two reviewers abstracted relevant information using standardized abstraction forms and graded article quality according to U.S.
- Data synthesis No randomized, controlled trial of screening for dementia has been completed.
- Brief screening tools can detect some persons with early dementia (positive predictive value Conclusions Screening tests can detect undiagnosed dementia.
- In persons with mild to moderate clinically detected Alzheimer disease, cholinesterase inhibitors are somewhat effective in slowing cognitive decline.
- The effect of cholinesterase inhibitors or other treatments on persons with dementia detected by screening is uncertain.
Why it matters
Screening tests can find some people with undiagnosed dementia, but no randomized trial of screening for dementia has been completed. In people whose mild to moderate Alzheimer disease is already clinically detected, cholinesterase inhibitors are somewhat effective at slowing cognitive decline, but whether these or other treatments help people found through screening is uncertain.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthHigh
How this study scored 58/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Annals of internal medicine) |
| Journal's citation record | 4 / 4 | Annals of Internal Medicine: journal h-index 648 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2003 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 580 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 23.2 citations a year over 25 year(s) since 2003 |
| Impact for its field and year | 4 / 6 | Cited 10.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 40 other studies in this library |
| Still being cited | 2 / 4 | Cited 27 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Kathleen N Lohr: h-index 92 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of North Carolina at Chapel Hill: institution h-index 1,674 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 12779304) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 58 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 28.
Later studies that cite this one
40 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments from nearby years
Also tagged “prevalence”
1,225 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,225 tagged studies.